A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
Principal Investigator
Graham WongOverview
Body Locations and Systems
Disorders and Conditions
ClinicalTrials.gov#
NCT02019264Status
Closed for RecruitmentStudy Start/End
Aug 1, 2014 to Dec 31, 2019Locations
Diamond Health Care Centre, Vancouver General Hospital
Name/Title
Naomi Uchida, Study Coordinator Phone
604-875-4521Email Address
naomi.uchida@ubc.caPurpose of Study
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with CV disease and/or multiple CV risk factors.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.